Aims: Frailty and sarcopenia are age-related morbid states, and a low body mass index (BMI) is a characteristic of frailty and cachexia. However, no common index for assessing these three muscle wasting states is available, making it difficult to understand the relationship among them. Peak oxygen uptake (peak VO 2 ), an index of life expectancy, may be a useful common index. Therefore, this study aimed to investigate the relationship among sarcopenia, frailty, and cachexia using age, BMI, and peak VO 2 . Methods and Results: Participants were 175 Japanese community dwelling older adults (58 men, 117 women; 77.6 years). We assessed biochemical, physiological, and physical factors, and symptoms associated with frailty, and cachexia. Peak VO 2 was assessed with a cardiopulmonary exercise test. Participants were classified into five groups: robust, pre-frail, frail, sarcopenia, and cachexia. We compared the groups by age, BMI, and peakVO 2 with average values and 95% confidence intervals (CIs). 17% (n=30) of participants were classified as robust, 40% (n=70) as pre-frail, 12% (n=21) as sarcopenia, 25% (n=44) as frail, and 6% (n=10) as cachexia. Significant differences were found in age (robust vs. frail, pre-frail vs. frail), BMI (robust vs. cachexia, pre-frail vs. cachexia, frail vs. cachexia), and peak VO 2 (robust vs. frail, robust vs. cachexia, pre-frail vs. cachexia) with average values and 95% CIs. Three dimensions among age, BMI and peak VO 2 revealed two trajectories (from robust to frailty via pre-frailty, and from robust to cachexia via sarcopenia) among muscle wasting diseases. Conclusions: This study revealed two trajectories among muscle wasting diseases.
Introduction
Sarcopenia (1), frailty (2) , and cachexia (3) are muscle wasting states that receive much attention in super aging societies. Previous reports indicated that sarcopenia prior to frailty, furthermore, indicated that sarcopenia may be one of a component of frailty (2) (4) . Similarly, previous reports indicated that sarcopenia and cachexia are overlapping each other, furthermore, indicated that cachexia may be one of a component of sarcopenia (5) (6) (7) (8) . Although these three morbid states are related, the exact relationship among them remains unknown. Reasons for this include: each state has a different definition (1) (2) (3) ; hand grip strength is a common parameter in these definitions, with the cutoff value for hand grip strength in sarcopenia often applied to frailty and cachexia; frailty and sarcopenia are age-related morbid states whereas cachexia is not; and body weight loss is characteristic of frailty and cachexia, but not of sarcopenia. Therefore, despite two common indices (i.e., age and body weight loss) for frailty and sarcopenia, frailty and cachexia, a lack of common useful indicators for the three states creates difficulty in understanding their relationship.
Peak oxygen uptake (peak VO 2 ) is known as an index of life expectancy (9) and a component of the cycle of frailty (2) . As sarcopenia, frailty, and cachexia are associated with mortality (2) (10) (11), we considered peak VO 2 as a common useful indicator to understand the relationship among the three states.
We hypothesized that age, body mass index (BMI), and peak VO 2 may be useful indices to understand the relationship among sarcopenia, frailty, and cachexia. Developing understanding of this area is clinically important; therefore, this study aimed to investigate the relationship among sarcopenia, frailty, and cachexia using age, BMI, and peak VO 2 , in Japanese community dwelling older adults.
Methods

Participants
Participants were 175 community dwelling older adults aged 65 years or over (58 men and 117 women) who lived in the Tokyo metropolitan area. Participants' mean age was 77.6 years (range 65-97 years). None of the participants were currently hospitalized, but all were receiving outpatient treatment at the Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology. Exclusion criteria were: age younger than 65 years, impaired vision, impaired hearing, musculoskeletal impairments that might interfere with the ability to perform the exercise test, and a clinically unstable condition. Potential participants who performed habitual exercise training were also excluded from the study. Habitual exercise training is defined as the performance of repetitive activity more than three times a week for the purpose of improving and/or maintaining physical performance such as aerobic training (i.e. walking, swimming), resistance training, and/or a combination of these methods (i.e. cycling). All willing participants were assigned to the study after application of the exclusion criteria. Participants' clinical characteristics are summarized in Table 1 and 2.
Laboratory investigations
Fasting blood samples for all participants were drawn from a large antecubital vein to determine hemoglobin, serum albumin, and high-sensitivity Creactive protein (hs-CRP). Hemoglobin levels were analyzed using Sysmex XE-5000 (Sysmex Corporation, Hyogo, Japan). Serum albumin levels were analyzed using the bromocresol purple assay (Shino-Test Corporation, Tokyo, Japan), and hs-CRP levels were analyzed using the CRP-Latex (II) immunoturbidimetric assay (Denka Seiken Corporation, Tokyo, Japan).
Skeletal muscle mass index (SMI), body mass index (BMI), and total body fat mass index
Appendicular skeletal muscle mass was measured using total body dual-energy X-ray absorptiometry (DEXA, Lunar iDXA, GE Healthcare, Tokyo, Japan). Appendicular skeletal muscle mass was considered the sum of the muscle mass of the four limbs, which was divided by height in meters squared to give the SMI (kg/m 2 ). Total body fat mass index was measured using total body dual-energy X-ray absorptiometry. The sum of the total fat mass index was calculated as total fat mass index divided by height in meters squared (kg/m 2 ). BMI was calculated as body weight divided by height in meters squared (kg/m 2 ).
Evaluation of physical performance
To test usual walking speed (m/s), we asked participants to walk along a straight 11-m walkway on a flat floor, once, at their usual speed. Walking speed was measured over a 5-m distance between markers placed 3 and 8 m from the start of the walkway. Two trials were conducted per participant, with the shorter time used in the analyses. Hand grip strength (HGS) is a valid indicator of overall muscle strength, and it is a particularly useful indicator of upper-extremity strength. HGS was assessed two times on each hand alternately using a Smedley-type JAMAR hand dynamometer (Sammons Preston Rolyan, Bolingbrook, IL, USA). The highest value was used in the analyses. All physical performance parameters for each participant were assessed by trained research assistants.
Assessment of robust, pre-frailty, frailty, sarcopenia, and cachexia
Frailty and pre-frailty were evaluated with the Japanese version of Cardiovascular Health Study (J-CHS) criteria (12) . Sarcopenia was evaluated with the Asian Working Group for Sarcopenia (AWGS) criteria (13) . Cachexia was evaluated according to "Cachexia: A new definition", except interleukin-6 (3).
AWGS criteria indicate the threshold for the SMI in sarcopenia is 7.0 kg/m 2 for men and 5.4 kg/m 2 for women, and that for hand grip strength is 26 kg for men and 18 kg for women and that for usual walking speed is 0.8 m/s (13) . J-CHS criteria indicate the threshold for usual walking speed in frailty is 1.0 m/s, and that for hand grip strength is 26 kg for men and 18 kg for women (12) . Cachexia criteria indicate that hand grip strength thresholds are 26 kg for men and 18 kg for women, and the SMI threshold is 7.0 kg/m 2 for men and 5.4 kg/m 2 for women (13) . According to the definition of cachexia (3), the thresholds of C-reactive protein, hemoglobin, and serum albumin are 0.5mg/dl, 12g/dl, and 3.2g/dl, respectively.
All participants completed a questionnaire that covered fatigability, anorexia, and low physical activity in daily life to assess status relating to frailty and cachexia. Participants were classified into robust, prefrail, frail, sarcopenia, or cachexia groups using the following method. First, we counted the number of participants with cachexia. After excluding those with cachexia, we counted the number of participants with frailty. Next, after excluding those with cachexia and frailty, we counted the number of participants with sarcopenia, according to the report "From sarcopenia to frailty" by Morley et al. (4) . After excluding participants with cachexia, frailty, and sarcopenia, we counted the number of participants who were pre-frail. Finally, after excluding those with cachexia, frailty, sarcopenia, and pre-frailty, the remaining participants were considered robust. The clinical characteristics of the five groups are summarized in Tables 1 and 2 . To assess the overlapping status, we investigated whether each group are also classified to robust, pre-frailty, sarcopenia, frailty and cachexia. Table 3 shows the number of participants in each group with overlapping status.
Cardiopulmonary exercise test (CPET)
All participants underwent a symptom-limited bicycle ergometer CPET using an upright, electromagnetically braked cycle ergometer (Aerobike Strength Ergo-8, Mitsubishi Electronic, Tokyo, Japan), a metabolic analyzer (Aeromonitor AE-310S, Minato Medical Science, Osaka, Japan), and an electrocardiogram (Stress test system ML-9000, Fukuda Denshi, Tokyo, Japan). The CPET began with a 3-min rest on the ergometer, followed by a 4-min warm-up at 0 watt and 60 rpm. During the exercise test, the load was increased incrementally by 15 watts per min. CPET parameters were measured from the beginning of the initial rest on the cycle ergometer until the end of the exercise session.
The CPET was terminated on the participant's request, if abnormal physiologic responses occurred (14) , or if a participant was unable to continue to perform the pedaling exercise correctly. Oxygen uptake (VO 2 ), carbon dioxide output (VCO 2 ), minute ventilation, tidal volume, and respiration frequency were smoothed with an 8-breath moving average. Peak VO 2 was defined as the highest VO 2 value obtained during the last minute of the CPET. When the respiratory exchange ratio (VCO 2 /VO 2 ) was less than 1.0 at peak exercise, the test was considered insufficient because of the participant's poor effort, and those peak exercise data were not used in the analyses. In this study, we explored peak VO 2 (ml/min) but not peak VO 2 /weight (ml/min/kg), because we combined BMI (and age) with peak VO 2 to investigate the relationship among sarcopenia, frailty, and cachexia.
Statistical analyses
A sample size of 140 participants was calculated for 80% power, α = 0.05, and an anticipated effect size of 0.30 using sample size software (G*Power 3.1.9.2., Germany). One-way analysis of variance (ANOVA) and chi-square tests were performed to compare the characteristics of participants in the five groups. All statistical analyses were performed with SPSS Version 22 (IBM Japan, Tokyo, Japan). Significance was set at p<0.05 for all tests.
Ethical considerations
This study was approved by the Ethics Committee of the Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (Authorization Number: 240301), and conformed to the principles outlined in the Declaration of Helsinki. All participants provided written informed consent before data collection. Table 1 shows the comparison of biochemical, physiological, and physical assessments for the five groups (robust, pre-frail, sarcopenia, frail, and cachexia) using one-way ANOVA. Of the 175 community dwelling older adults, 17% (n=30) were robust, 40% (n=70) were pre-frail, 12% (n=21) were sarcopenia, 25% (n=44) had frail, and 6% (n=10) had cachexia. Significant differences were seen in age (years) between the robust and frail groups (75.4±5.7 vs. 80.6±6.7), and the pre-frail and frail groups (77.2±6.3 vs. 80.6±6.7). Significant differences were seen in BMI (kg/m 2 ) between the robust and cachexia groups (23.6±3.5 vs. 18.2±1.1), the pre-frail and cachexia groups (23.4±3.3 vs. 18.2±1.1), and the frail and cachexia groups (23.2±3.5 vs. 18.2±1.1). There were significant differences in peak VO 2 (ml/min) between the robust and frail groups (1065.0±244.5 vs. 788.3±262.5), the robust and cachexia groups (1065.0±244.5 vs. 667.0±306.4), and the pre-frail and cachexia groups (927.9±301.8 vs. 667.0±306.4). In addition, significant differences were seen in SMI (kg/m 2 ) between the robust and sarcopenia groups (6.4±0.8 vs. 5.4±0.8), the pre-frail and sarcopenia groups (6.3±0.8 vs. 5.4±0.8), the frail and sarcopenia groups (6.3±0.9 vs. 5.4±0.8), the robust and cachexia groups (6.4±0.8 vs. 5.4±0.6), the pre-frail and cachexia groups (6.3±0.8 vs. 5.4±0.6), and the frailty and cachexia groups (6.3±0.9 vs. 5.4±0.6). There were also significant differences in total body fat mass index between robust and cachexia (8.0±2.7 vs. 3.9±1.0), pre-frailty and cachexia (7.6±2.4 vs. 3.9±1.0), sarcopenia and cachexia (7.0±2.6 vs. 3.9±1.0), and frailty and cachexia (7.5±2.9 vs. 3.9±1.0). There were also significant differences in usual walking speed (m/s) between the robust and frail groups (1.2±0.1 vs. 0.8±0.2), the pre-frail and frail groups (1.0±0.2 vs. 0.8±0.2), and the sarcopenia and frail groups (1.0±0.2 vs. 0.8±0.2). Significant differences were seen in peak VO 2 /heart rate between robust and cachexia, and prefrailty and cachexia, and seen in VE/VCO 2 slope between robust and cachexia, pre-frailty and cachexia, and frail and cachexia. Table 2 shows the comparisons with the comorbidities among robust, pre-frail, sarcopenia, frail and cachexia participants using chi-square tests. Significant differences were seen in sex and prevalence of hypertension, chronic heart failure, chronic obstructive pulmonary disease, chronic kidney disease, cancer, fatigability, low physical activity, and anorexia. Table 3 shows the number of participants with overlapping muscle wasting states based on the original definitions. Of 10 participants in the cachexia group, two were also classified as sarcopenia and prefrail, one as frail, and seven as sarcopenia and frail. Of the 44 participants in the frail group, 32 were also classified as frail and 12 as sarcopenia. All 21 participants in the sarcopenia group were classified with overlapping pre-frailty. Of all participants (n=175), the prevalence rates of overlapping states were 17% (n=30) for robust, 53% (n=93) for pre-frailty, 24% (n=42) for sarcopenia, 30% (n=52) for frailty, and 6% (n=10) for cachexia. Figure 1 shows the relationship between age and peak VO 2 ( Figure 1A ), BMI and peak VO 2 ( Figure 1B) , and age and BMI ( Figure 1C) 2 ), and peak VO 2 667.0 ml/min (447.9-886.2 ml/min). Figure 2 shows the relationship for age, BMI, and peak VO 2 in the five groups in three dimensions using gnuplot software (ver.5.2 patch level 0). The average points for age, BMI, and peak VO 2 (the same as in Figure 1 ) are plotted for the robust, pre-frail, sarcopenia, frail, and cachexia groups. Cachexia + frailty + sarcopenia Fig. 1 The relationship between peak oxygen uptake (VO 2 ) and age is shown in Figure 1A , peak VO 2 and body mass index (BMI) in Figure 1B , and BMI and age in Figure 1C . The average values and 95% confidence intervals for age, BMI, and peak VO 2 among the robust, pre-frail, sarcopenia, frail, and cachexia groups were as follows. The relationship among age and body mass index (BMI) and peak oxygen uptake (VO 2 ) is shown in three dimensions: A is the view from the top, B is a front view with BMI on the horizontal axis, and C is a front view with age on the horizontal axis. The average points for age, BMI, and peakVO 2 are plotted for the robust, pre-frailty, sarcopenia, frailty, and cachexia groups. 
Results
Discussion
Our study using data from community dwelling older adults aged 65 years or over who lived in the Tokyo metropolitan area showed the prevalence of robust was 17%, pre-frailty was 40%, sarcopenia was 12%, frailty was 25%, and cachexia was 6%. A previous study reported the prevalence of robust was 44.4%, pre-frailty was 48.1%, and frailty was 7.4% (15) . Similarly, the prevalence of sarcopenia in Japan was previously reported as 2.5%-28.0% in males and 2.3%-11.7% in females (16) , and that of cachexia was 0.5%-1.0% (17) . However, from the perspective of overlapping states, we showed the prevalence of robust was 17% (n=30), pre-frailty was 53% (n=93), sarcopenia was 24% (n=42), frailty was 30% (n=52), and cachexia was 6% (n=10). Our study involving geriatric clinic outpatients showed a high prevalence of these muscle wasting states, especially for frailty and cachexia, and a low prevalence of robust older adults. Konishi et al. reported that using the same cachexia definition in Japan as used in Western countries leads to gross overestimation of the prevalence of cachexia because of lower BMI and body weight (18) . Although this study is not representative of community dwelling older adults, it is representative of community dwelling older adults with chronic disease(s) in the Tokyo metropolitan area in Japan.
This study aimed to show the relationship among three muscle wasting states. We found that peak VO 2 is one of the useful indicators for sarcopenia, frailty, and cachexia (including robust and pre-frail older adults). The relationships between peak VO 2 and age ( Figure 1A ), peak VO 2 and BMI ( Figure 1B) , and BMI and age ( Figure 1C ) may be useful in understanding the relation among these muscle wasting states.
Interestingly, Figures 1A-C suggests there are two trajectories from robust; one is "from robust to frailty via pre-frailty" (i.e. aging-based trajectory), and the other is "from robust to cachexia via sarcopenia" (disease-based trajectory). Furthermore, interestingly, these two trajectories shows the significant difference between sarcopenia which is in the aging-based trajectory, as 12 among all of 44 frail participants, and sarcopenia which is in the disease-based trajectory, as all of 21 sarcopenia participants (Table 3, Figure 1 A-C) . Although, Muscaritoli M et al reported that cachexiarelated sarcopenia must be distinguished from agerelated sarcopenia (6) , it is difficult to distinguish in clinical practice, so far. This result might indicate that sarcopenia in the aging-based trajectory corresponds to age-related sarcopenia, and sarcopenia in the diseasebased trajectory corresponds to cachexia-related sarcopenia. Additionally, this result might be indicated that the prevalence of age-related sarcopenia and cachexia-related sarcopenia among community dwelling older adults are 6.9% and 12.0%. After clarifying the relationship among these three muscle wasting states using two dimensions, we showed three dimensions with age, BMI and peak VO 2 , to understand the relation, more easily, among these three muscle wasting states (Figure 2A-C) . This three-dimensional scatter plot showed a "valley of aging" and two cliffs toward this valley (i.e. aging-and disease-based trajectories), in this cross-sectional study (Figures 2A-C) . One shows slowly decreasing peak VO 2 , while maintaining BMI along with aging (aging-based trajectory). The other shows rapidly decreasing peak VO 2 and BMI, regardless of aging (disease-based trajectory).
Additionally, based on Table 3 , it might be indicated that there are no sarcopenia which does not co-exist with pre-frailty, and no cachexia which does not co-exist with pre-frailty and/or frailty, in the disease-based trajectory. Therefore, it may be reasonable to understand that there are three layers : robust layer ( , peak VO 2 788.3±262.5 ml/min), and despite younger age compared with those who were pre-frail and frail, status falling to the prefrailty layer may be considered cachexia-related sarcopenia; similarly, status falling to the pre-frailty to the frailty layer may be considered cachexia.
This study showed that age, BMI, and peakVO 2 were useful measures, although evaluating peakVO 2 among older adults is sometimes challenging. We previously reported a novel method of predicting peakVO 2 with relatively high quality using the following formula compared with evaluated peak VO 2 (r=0.74, p<0.001) (19) Therefore, it may be useful and helpful for clinicians to determine the status of patients using age, BMI, and this formula to predict peak VO 2 .
This study had several limitations. We did not evaluate interleukin-6, which is an important parameter for cachexia. A larger sample is needed to understand the prevalence of these three muscle wasting states based on community-dwelling people, rather than clinical outpatients. In addition, a larger sample is needed to understand prevalence rates by sex, and to investigate the prevalence of sarcopenic obesity. Although, this study shows the potential usefulness of SMI as an alternative for BMI, the sample size was small because it needs divide into both of sex. In future, it needs to investigate whether age, BMI, and peak VO 2 could be useful to understand the relationship among sarcopenia, frailty, and cachexia in other ethnicities. Additionally, it needs to investigate the change of these states with nutritional intervention and/or exercise intervention, as longitudinal study. Finally, the participants of this study were based on hospital sample, and based on chronic disease(s); therefore, there is a limitation to applicate to general elderly population.
In conclusion, this cross-sectional, a pilot study showed the relationship among these muscle wasting states, and the two distinct trajectories among these muscle wasting states on the 3-dimensional age-BMIpeak VO 2 scatterplot.
